FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2029658169> ?p ?o ?g. }

• W2029658169 endingPage "1047" @default.
• W2029658169 startingPage "1040" @default.
• W2029658169 abstract "The present study was undertaken to examine whether ribozymes cleaving specifically cathepsin L (CL) mRNA are able to decrease the synthesis of CL protease in rheumatoid arthritis synovial fibroblasts (RA-SF) and thereby reduce the invasiveness into cartilage both in vitro and in the SCID mouse coimplantation model of RA. Two different ribozymes that cleave CL mRNA specifically at positions 533 (RzCL533) and 790 (RzCL790) were generated. Using retroviral gene transfer, RA-SF were transduced with the ribozyme constructs or the empty vector. To examine the effect of the ribozymes on the mRNA level, quantitative analysis for CL mRNA was performed using real-time PCR. For evaluation on the protein level, ELISA using specific anti-CL antibodies was performed. In addition, transduced RA-SF were examined in vitro in a three-dimensional destruction assay evaluating their ability to degrade extracellular matrix produced by human chondrocytes. Matrix destruction was monitored by the release of soluble glycosaminoglycans (sGAG). Using the in vivo SCID mouse coimplantation model of RA, RzCL533-transduced RA-SF and control cells were coimplanted with human cartilage for 60 days. After being killed, invasion of RA-SF into the cartilage was evaluated by using a semiquantitative score. Transduction of RA-SF with RzCL533 and RzCL790 ribozymes decreased significantly the expression of CL mRNA to 44% (range 25–62%) and 20% (range 1–43%), respectively, when compared to mock-transduced cells. The protein concentration of CL in the cell culture supernatants of transduced RA-SF was decreased from 16.0 ng/ml in the mock constructs to 4.1 and 8.2 ng/ml (mean), respectively. Using the in vitro cartilage destruction assay, the release of sGAG decreased to 46 and 60%, respectively, after 14 days when compared to mock-transduced cells. In the SCID mouse coimplantation model of RA, RzCL533-transduced RA-SF revealed a significant lower cartilage invasion when compared to mock and untransduced cells. Using retroviral gene transfer, ribozymes cleaving CL mRNA inhibit specifically the synthesis of this matrix-degrading enzyme and reduce cartilage destruction in in vitro and in vivo models. Our study therefore suggests that ribozymes targeting CL could be a novel and efficient tool to inhibit joint destruction in RA." @default.
• W2029658169 created "2016-06-24" @default.
• W2029658169 creator A5014212884 @default.
• W2029658169 creator A5026582019 @default.
• W2029658169 creator A5027428785 @default.
• W2029658169 creator A5029329633 @default.
• W2029658169 creator A5066992396 @default.
• W2029658169 creator A5073770232 @default.
• W2029658169 creator A5073899811 @default.
• W2029658169 creator A5086602394 @default.
• W2029658169 creator A5088115834 @default.
• W2029658169 creator A5091729439 @default.
• W2029658169 date "2004-05-27" @default.
• W2029658169 modified "2023-10-17" @default.
• W2029658169 title "Targeting cathepsin L (CL) by specific ribozymes decreases CL protein synthesis and cartilage destruction in rheumatoid arthritis" @default.
• W2029658169 cites W1569484918 @default.
• W2029658169 cites W1792226828 @default.
• W2029658169 cites W1860619571 @default.
• W2029658169 cites W1965205687 @default.
• W2029658169 cites W1973425560 @default.
• W2029658169 cites W1986768873 @default.
• W2029658169 cites W1993040702 @default.
• W2029658169 cites W1994661064 @default.
• W2029658169 cites W2010266021 @default.
• W2029658169 cites W201066153 @default.
• W2029658169 cites W2021922468 @default.
• W2029658169 cites W2029596865 @default.
• W2029658169 cites W2031879930 @default.
• W2029658169 cites W2032037361 @default.
• W2029658169 cites W2037213615 @default.
• W2029658169 cites W2044002373 @default.
• W2029658169 cites W2052457757 @default.
• W2029658169 cites W2055395264 @default.
• W2029658169 cites W2060252723 @default.
• W2029658169 cites W2063035603 @default.
• W2029658169 cites W2068602081 @default.
• W2029658169 cites W2071480749 @default.
• W2029658169 cites W2073946388 @default.
• W2029658169 cites W2081618261 @default.
• W2029658169 cites W2083002895 @default.
• W2029658169 cites W2098589989 @default.
• W2029658169 cites W2102859558 @default.
• W2029658169 cites W2115109015 @default.
• W2029658169 cites W2138329420 @default.
• W2029658169 cites W2148191159 @default.
• W2029658169 cites W2152348310 @default.
• W2029658169 cites W2255337241 @default.
• W2029658169 cites W2318283418 @default.
• W2029658169 cites W2321857560 @default.
• W2029658169 cites W2399319395 @default.
• W2029658169 cites W4251138628 @default.
• W2029658169 doi "https://doi.org/10.1038/sj.gt.3302265" @default.
• W2029658169 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15164093" @default.
• W2029658169 hasPublicationYear "2004" @default.
• W2029658169 type Work @default.
• W2029658169 sameAs 2029658169 @default.
• W2029658169 citedByCount "53" @default.
• W2029658169 countsByYear W20296581692012 @default.
• W2029658169 countsByYear W20296581692013 @default.
• W2029658169 countsByYear W20296581692014 @default.
• W2029658169 countsByYear W20296581692015 @default.
• W2029658169 countsByYear W20296581692016 @default.
• W2029658169 countsByYear W20296581692017 @default.
• W2029658169 countsByYear W20296581692019 @default.
• W2029658169 countsByYear W20296581692020 @default.
• W2029658169 countsByYear W20296581692021 @default.
• W2029658169 crossrefType "journal-article" @default.
• W2029658169 hasAuthorship W2029658169A5014212884 @default.
• W2029658169 hasAuthorship W2029658169A5026582019 @default.
• W2029658169 hasAuthorship W2029658169A5027428785 @default.
• W2029658169 hasAuthorship W2029658169A5029329633 @default.
• W2029658169 hasAuthorship W2029658169A5066992396 @default.
• W2029658169 hasAuthorship W2029658169A5073770232 @default.
• W2029658169 hasAuthorship W2029658169A5073899811 @default.
• W2029658169 hasAuthorship W2029658169A5086602394 @default.
• W2029658169 hasAuthorship W2029658169A5088115834 @default.
• W2029658169 hasAuthorship W2029658169A5091729439 @default.
• W2029658169 hasBestOaLocation W20296581691 @default.
• W2029658169 hasConcept C104317684 @default.
• W2029658169 hasConcept C105580179 @default.
• W2029658169 hasConcept C105702510 @default.
• W2029658169 hasConcept C153911025 @default.
• W2029658169 hasConcept C167844969 @default.
• W2029658169 hasConcept C181199279 @default.
• W2029658169 hasConcept C185592680 @default.
• W2029658169 hasConcept C189165786 @default.
• W2029658169 hasConcept C202751555 @default.
• W2029658169 hasConcept C2780034444 @default.
• W2029658169 hasConcept C2780550940 @default.
• W2029658169 hasConcept C55493867 @default.
• W2029658169 hasConcept C67705224 @default.
• W2029658169 hasConcept C76346623 @default.
• W2029658169 hasConcept C86803240 @default.
• W2029658169 hasConcept C95444343 @default.
• W2029658169 hasConceptScore W2029658169C104317684 @default.
• W2029658169 hasConceptScore W2029658169C105580179 @default.
• W2029658169 hasConceptScore W2029658169C105702510 @default.
• W2029658169 hasConceptScore W2029658169C153911025 @default.

• next